New Haven antibiotics developer Rib-X Pharmaceuticals Inc. has taken in $5.5 million of a planned $22 million offering combining debt, warrants and options, Mass High Tech reports, citing a regulatory filing.
The filing with the U.S. Securities and Exchange Commission does not identify the investors of the offering.
However, in addition to CEO Mark Leuchtenberger and CFO Robert Conerly, the filing identifies Rib-X’s board of directors: retired Pfizer CEO George Milne, executive chair of Rib-X; C. Boyd Clarke, retired president and CEO of Neose Technologies Inc.; Cecilia Gonzalo and Jonathan Leff of Warburg Pincus LLC; and Harry Penner Jr., chairman and CEO of Nascent BioScience LLC.
In early January, Rib-X brought in $20 million in a financing, led by Warburg Pincus, to support an upcoming Phase 2b study of its delafloxacin antibiotic drug for treating infections resistant to conventional anti-bacterial drugs.
On its website, the company lists its investors, which include Connecticut Innnovations Inc., ABS Ventures, Axion Venture Partners LP, Cardinal Partners, EuclidSR Partners, MedImmune Ventures Inc., Oxford Bioscience Partners, Radius Ventures LLC, SR One Venture Investments, Warburg Pincus LLC and Vox Equity Partners I & II LLP.
Rib-X was founded in 2001 by Yale University colleagues Peter Moore, William Jorgensen and Thomas Steitz, winner of a portion of the 2009 Nobel Prize in Chemistry for his work describing the structure and function of the ribosome.
